Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic.
Identifieur interne : 000650 ( Main/Exploration ); précédent : 000649; suivant : 000651Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic.
Auteurs : Javier Martin-Broto [Espagne] ; Nadia Hindi [Espagne] ; Samuel Aguiar [Brésil] ; Ronald Badilla-González [Costa Rica] ; Victor Castro-Oliden [Pérou] ; Matias Chac N [Argentine] ; Raquel Correa-Generoso [Espagne] ; Enrique De Lava [Espagne] ; Davide María Donati [Italie] ; Mikael Eriksson [Suède] ; Martin Falla-Jimenez [Pérou] ; Gisela German [Argentine] ; Maria Leticia Gobo Silva [Brésil] ; Francois Gouin [France] ; Alessandro Gronchi [Italie] ; Juan Carlos Haro-Varas [Pérou] ; Natalia Jiménez-Brenes [Costa Rica] ; Bernd Kasper [Allemagne] ; Celso Abdon Lopes De Mello [Brésil] ; Robert Maki [États-Unis] ; Paula Martínez-Delgado [Espagne] ; Hector Martínez-Said [Mexique] ; Jorge Luis Martinez-Tlahuel [Mexique] ; Jose Manuel Morales-Pérez [Espagne] ; Francisco Cristobal Mu Oz-Casares [Espagne] ; Suely A. Nakagawa [Brésil] ; Eduardo Jose Ortiz-Cruz [Espagne] ; Emanuela Palmerini [Italie] ; Shreyaskumar Patel [États-Unis] ; David S. Moura [Espagne] ; Silvia Stacchiotti [Italie] ; Marie Pierre Sunyach [France] ; Claudia M. Valverde [Espagne] ; Federico Waisberg [Argentine] ; Jean-Yves Blay [France]Source :
- The oncologist [ 1549-490X ] ; 2020.
Abstract
BACKGROUND
The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID-19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care.
MATERIAL AND METHODS
A total of 125 recommendations were proposed in soft-tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2-3 months, respectively. The consensus level for each recommendation was classified as "strongly recommended" (SR) if more than 90% of experts agreed, "recommended" (R) if 75%-90% of experts agreed and "no consensus" (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European-Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology-Magnitude of clinical benefit scale was applied to systemic-treatment recommendations to support prioritization.
RESULTS
There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher-priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower-priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively).
CONCLUSION
The consensus on 115 of 125 recommendations indicates a high-level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.
IMPLICATIONS FOR PRACTICE
The Sarcoma European-Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID-19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID-19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower-priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology-Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.
DOI: 10.1634/theoncologist.2020-0516
PubMed: 32888360
Affiliations:
- Allemagne, Argentine, Brésil, Costa Rica, Espagne, France, Italie, Mexique, Pérou, Suède, États-Unis
- Auvergne-Rhône-Alpes, Bade-Wurtemberg, Catalogne, Communauté de Madrid, District de Karlsruhe, Lombardie, Pennsylvanie, Rhône-Alpes, Texas, État de São Paulo
- Barcelone, Lyon, Madrid, Mannheim, Milan, São Paulo
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic.</title><author><name sortKey="Martin Broto, Javier" sort="Martin Broto, Javier" uniqKey="Martin Broto J" first="Javier" last="Martin-Broto">Javier Martin-Broto</name><affiliation wicri:level="1"><nlm:affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla</wicri:regionArea><wicri:noRegion>Sevilla</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Hindi, Nadia" sort="Hindi, Nadia" uniqKey="Hindi N" first="Nadia" last="Hindi">Nadia Hindi</name><affiliation wicri:level="1"><nlm:affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla</wicri:regionArea><wicri:noRegion>Sevilla</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Aguiar, Samuel" sort="Aguiar, Samuel" uniqKey="Aguiar S" first="Samuel" last="Aguiar">Samuel Aguiar</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pelvic Surgery, A.C. Camargo Cancer Center, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Department of Pelvic Surgery, A.C. Camargo Cancer Center, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Badilla Gonzalez, Ronald" sort="Badilla Gonzalez, Ronald" uniqKey="Badilla Gonzalez R" first="Ronald" last="Badilla-González">Ronald Badilla-González</name><affiliation wicri:level="1"><nlm:affiliation>Department of medical oncology, Rafael Ángel Calderón Guardia Hospital, San José, Costa Rica.</nlm:affiliation><country xml:lang="fr">Costa Rica</country><wicri:regionArea>Department of medical oncology, Rafael Ángel Calderón Guardia Hospital, San José</wicri:regionArea><wicri:noRegion>San José</wicri:noRegion></affiliation></author><author><name sortKey="Castro Oliden, Victor" sort="Castro Oliden, Victor" uniqKey="Castro Oliden V" first="Victor" last="Castro-Oliden">Victor Castro-Oliden</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.</nlm:affiliation><country xml:lang="fr">Pérou</country><wicri:regionArea>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima</wicri:regionArea><wicri:noRegion>Lima</wicri:noRegion></affiliation></author><author><name sortKey="Chac N, Matias" sort="Chac N, Matias" uniqKey="Chac N M" first="Matias" last="Chac N">Matias Chac N</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Correa Generoso, Raquel" sort="Correa Generoso, Raquel" uniqKey="Correa Generoso R" first="Raquel" last="Correa-Generoso">Raquel Correa-Generoso</name><affiliation wicri:level="1"><nlm:affiliation>Radiotherapy Department, Virgen de la Victoria University Hospital, Málaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Radiotherapy Department, Virgen de la Victoria University Hospital, Málaga</wicri:regionArea><wicri:noRegion>Málaga</wicri:noRegion></affiliation></author><author><name sortKey="De Lava, Enrique" sort="De Lava, Enrique" uniqKey="De Lava E" first="Enrique" last="De Lava">Enrique De Lava</name><affiliation wicri:level="1"><nlm:affiliation>Pathology Department, University Hospital Virgen del Rocío, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pathology Department, University Hospital Virgen del Rocío, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>CIBERONC, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>CIBERONC, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Donati, Davide Maria" sort="Donati, Davide Maria" uniqKey="Donati D" first="Davide María" last="Donati">Davide María Donati</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Orthopedic Pathology and Osteoarticular Tissue Regeneration, Rizzoli Orthopedic Institute, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Orthopedic Pathology and Osteoarticular Tissue Regeneration, Rizzoli Orthopedic Institute, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Eriksson, Mikael" sort="Eriksson, Mikael" uniqKey="Eriksson M" first="Mikael" last="Eriksson">Mikael Eriksson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Skane University Hospital-Lund, Lund, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Medical Oncology, Skane University Hospital-Lund, Lund</wicri:regionArea><wicri:noRegion>Lund</wicri:noRegion></affiliation></author><author><name sortKey="Falla Jimenez, Martin" sort="Falla Jimenez, Martin" uniqKey="Falla Jimenez M" first="Martin" last="Falla-Jimenez">Martin Falla-Jimenez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Breast and Soft Tissues Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.</nlm:affiliation><country xml:lang="fr">Pérou</country><wicri:regionArea>Department of Breast and Soft Tissues Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima</wicri:regionArea><wicri:noRegion>Lima</wicri:noRegion></affiliation></author><author><name sortKey="German, Gisela" sort="German, Gisela" uniqKey="German G" first="Gisela" last="German">Gisela German</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hospital Oncológico Provincial, Córdoba, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Department of Medical Oncology, Hospital Oncológico Provincial, Córdoba</wicri:regionArea><wicri:noRegion>Córdoba</wicri:noRegion></affiliation></author><author><name sortKey="Gobo Silva, Maria Leticia" sort="Gobo Silva, Maria Leticia" uniqKey="Gobo Silva M" first="Maria Leticia" last="Gobo Silva">Maria Leticia Gobo Silva</name><affiliation wicri:level="3"><nlm:affiliation>Department of Radiation Therapy, A.C. Camargo Cancer Center, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Department of Radiation Therapy, A.C. Camargo Cancer Center, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Gouin, Francois" sort="Gouin, Francois" uniqKey="Gouin F" first="Francois" last="Gouin">Francois Gouin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Orthopedic Surgery, Centre León Bérard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Orthopedic Surgery, Centre León Bérard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Gronchi, Alessandro" sort="Gronchi, Alessandro" uniqKey="Gronchi A" first="Alessandro" last="Gronchi">Alessandro Gronchi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Haro Varas, Juan Carlos" sort="Haro Varas, Juan Carlos" uniqKey="Haro Varas J" first="Juan Carlos" last="Haro-Varas">Juan Carlos Haro-Varas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.</nlm:affiliation><country xml:lang="fr">Pérou</country><wicri:regionArea>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima</wicri:regionArea><wicri:noRegion>Lima</wicri:noRegion></affiliation></author><author><name sortKey="Jimenez Brenes, Natalia" sort="Jimenez Brenes, Natalia" uniqKey="Jimenez Brenes N" first="Natalia" last="Jiménez-Brenes">Natalia Jiménez-Brenes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, San Vicente de Paúl Hospital, Heredia, Costa Rica.</nlm:affiliation><country xml:lang="fr">Costa Rica</country><wicri:regionArea>Department of Medical Oncology, San Vicente de Paúl Hospital, Heredia</wicri:regionArea><wicri:noRegion>Heredia</wicri:noRegion></affiliation></author><author><name sortKey="Kasper, Bernd" sort="Kasper, Bernd" uniqKey="Kasper B" first="Bernd" last="Kasper">Bernd Kasper</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Mannheim University Medical Center, Mannheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Medical Oncology, Mannheim University Medical Center, Mannheim</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Lopes De Mello, Celso Abdon" sort="Lopes De Mello, Celso Abdon" uniqKey="Lopes De Mello C" first="Celso Abdon" last="Lopes De Mello">Celso Abdon Lopes De Mello</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Maki, Robert" sort="Maki, Robert" uniqKey="Maki R" first="Robert" last="Maki">Robert Maki</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Martinez Delgado, Paula" sort="Martinez Delgado, Paula" uniqKey="Martinez Delgado P" first="Paula" last="Martínez-Delgado">Paula Martínez-Delgado</name><affiliation wicri:level="1"><nlm:affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla</wicri:regionArea><wicri:noRegion>Sevilla</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Said, Hector" sort="Martinez Said, Hector" uniqKey="Martinez Said H" first="Hector" last="Martínez-Said">Hector Martínez-Said</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Tlahuel, Jorge Luis" sort="Martinez Tlahuel, Jorge Luis" uniqKey="Martinez Tlahuel J" first="Jorge Luis" last="Martinez-Tlahuel">Jorge Luis Martinez-Tlahuel</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, Instituto Nacional de Cancerología, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Surgery, Instituto Nacional de Cancerología, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Morales Perez, Jose Manuel" sort="Morales Perez, Jose Manuel" uniqKey="Morales Perez J" first="Jose Manuel" last="Morales-Pérez">Jose Manuel Morales-Pérez</name><affiliation wicri:level="1"><nlm:affiliation>Radiology Department, University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Radiology Department, University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Mu Oz Casares, Francisco Cristobal" sort="Mu Oz Casares, Francisco Cristobal" uniqKey="Mu Oz Casares F" first="Francisco Cristobal" last="Mu Oz-Casares">Francisco Cristobal Mu Oz-Casares</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Surgery, University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Nakagawa, Suely A" sort="Nakagawa, Suely A" uniqKey="Nakagawa S" first="Suely A" last="Nakagawa">Suely A. Nakagawa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Orthopedics, A.C. Camargo Cancer Center, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Department of Orthopedics, A.C. Camargo Cancer Center, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Ortiz Cruz, Eduardo Jose" sort="Ortiz Cruz, Eduardo Jose" uniqKey="Ortiz Cruz E" first="Eduardo Jose" last="Ortiz-Cruz">Eduardo Jose Ortiz-Cruz</name><affiliation wicri:level="3"><nlm:affiliation>Orthopedic Surgery and Traumatology Department, La Paz University Hospital, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Orthopedic Surgery and Traumatology Department, La Paz University Hospital, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Palmerini, Emanuela" sort="Palmerini, Emanuela" uniqKey="Palmerini E" first="Emanuela" last="Palmerini">Emanuela Palmerini</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Rizzoli Orthopedic Institute, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical Oncology, Rizzoli Orthopedic Institute, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Patel, Shreyaskumar" sort="Patel, Shreyaskumar" uniqKey="Patel S" first="Shreyaskumar" last="Patel">Shreyaskumar Patel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Moura, David S" sort="Moura, David S" uniqKey="Moura D" first="David S" last="Moura">David S. Moura</name><affiliation wicri:level="1"><nlm:affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla</wicri:regionArea><wicri:noRegion>Sevilla</wicri:noRegion></affiliation></author><author><name sortKey="Stacchiotti, Silvia" sort="Stacchiotti, Silvia" uniqKey="Stacchiotti S" first="Silvia" last="Stacchiotti">Silvia Stacchiotti</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Sunyach, Marie Pierre" sort="Sunyach, Marie Pierre" uniqKey="Sunyach M" first="Marie Pierre" last="Sunyach">Marie Pierre Sunyach</name><affiliation wicri:level="3"><nlm:affiliation>Department of Radiation Therapy, Centre León Bérard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Radiation Therapy, Centre León Bérard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Valverde, Claudia M" sort="Valverde, Claudia M" uniqKey="Valverde C" first="Claudia M" last="Valverde">Claudia M. Valverde</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Vall d'Hebron Hospital, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Vall d'Hebron Hospital, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Waisberg, Federico" sort="Waisberg, Federico" uniqKey="Waisberg F" first="Federico" last="Waisberg">Federico Waisberg</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Centre León Bérard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Centre León Bérard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32888360</idno><idno type="pmid">32888360</idno><idno type="doi">10.1634/theoncologist.2020-0516</idno><idno type="wicri:Area/Main/Corpus">000227</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000227</idno><idno type="wicri:Area/Main/Curation">000227</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000227</idno><idno type="wicri:Area/Main/Exploration">000227</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic.</title><author><name sortKey="Martin Broto, Javier" sort="Martin Broto, Javier" uniqKey="Martin Broto J" first="Javier" last="Martin-Broto">Javier Martin-Broto</name><affiliation wicri:level="1"><nlm:affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla</wicri:regionArea><wicri:noRegion>Sevilla</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Hindi, Nadia" sort="Hindi, Nadia" uniqKey="Hindi N" first="Nadia" last="Hindi">Nadia Hindi</name><affiliation wicri:level="1"><nlm:affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla</wicri:regionArea><wicri:noRegion>Sevilla</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Aguiar, Samuel" sort="Aguiar, Samuel" uniqKey="Aguiar S" first="Samuel" last="Aguiar">Samuel Aguiar</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pelvic Surgery, A.C. Camargo Cancer Center, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Department of Pelvic Surgery, A.C. Camargo Cancer Center, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Badilla Gonzalez, Ronald" sort="Badilla Gonzalez, Ronald" uniqKey="Badilla Gonzalez R" first="Ronald" last="Badilla-González">Ronald Badilla-González</name><affiliation wicri:level="1"><nlm:affiliation>Department of medical oncology, Rafael Ángel Calderón Guardia Hospital, San José, Costa Rica.</nlm:affiliation><country xml:lang="fr">Costa Rica</country><wicri:regionArea>Department of medical oncology, Rafael Ángel Calderón Guardia Hospital, San José</wicri:regionArea><wicri:noRegion>San José</wicri:noRegion></affiliation></author><author><name sortKey="Castro Oliden, Victor" sort="Castro Oliden, Victor" uniqKey="Castro Oliden V" first="Victor" last="Castro-Oliden">Victor Castro-Oliden</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.</nlm:affiliation><country xml:lang="fr">Pérou</country><wicri:regionArea>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima</wicri:regionArea><wicri:noRegion>Lima</wicri:noRegion></affiliation></author><author><name sortKey="Chac N, Matias" sort="Chac N, Matias" uniqKey="Chac N M" first="Matias" last="Chac N">Matias Chac N</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Correa Generoso, Raquel" sort="Correa Generoso, Raquel" uniqKey="Correa Generoso R" first="Raquel" last="Correa-Generoso">Raquel Correa-Generoso</name><affiliation wicri:level="1"><nlm:affiliation>Radiotherapy Department, Virgen de la Victoria University Hospital, Málaga, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Radiotherapy Department, Virgen de la Victoria University Hospital, Málaga</wicri:regionArea><wicri:noRegion>Málaga</wicri:noRegion></affiliation></author><author><name sortKey="De Lava, Enrique" sort="De Lava, Enrique" uniqKey="De Lava E" first="Enrique" last="De Lava">Enrique De Lava</name><affiliation wicri:level="1"><nlm:affiliation>Pathology Department, University Hospital Virgen del Rocío, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pathology Department, University Hospital Virgen del Rocío, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>CIBERONC, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>CIBERONC, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Donati, Davide Maria" sort="Donati, Davide Maria" uniqKey="Donati D" first="Davide María" last="Donati">Davide María Donati</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Orthopedic Pathology and Osteoarticular Tissue Regeneration, Rizzoli Orthopedic Institute, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Orthopedic Pathology and Osteoarticular Tissue Regeneration, Rizzoli Orthopedic Institute, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Eriksson, Mikael" sort="Eriksson, Mikael" uniqKey="Eriksson M" first="Mikael" last="Eriksson">Mikael Eriksson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Skane University Hospital-Lund, Lund, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Medical Oncology, Skane University Hospital-Lund, Lund</wicri:regionArea><wicri:noRegion>Lund</wicri:noRegion></affiliation></author><author><name sortKey="Falla Jimenez, Martin" sort="Falla Jimenez, Martin" uniqKey="Falla Jimenez M" first="Martin" last="Falla-Jimenez">Martin Falla-Jimenez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Breast and Soft Tissues Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.</nlm:affiliation><country xml:lang="fr">Pérou</country><wicri:regionArea>Department of Breast and Soft Tissues Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima</wicri:regionArea><wicri:noRegion>Lima</wicri:noRegion></affiliation></author><author><name sortKey="German, Gisela" sort="German, Gisela" uniqKey="German G" first="Gisela" last="German">Gisela German</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hospital Oncológico Provincial, Córdoba, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Department of Medical Oncology, Hospital Oncológico Provincial, Córdoba</wicri:regionArea><wicri:noRegion>Córdoba</wicri:noRegion></affiliation></author><author><name sortKey="Gobo Silva, Maria Leticia" sort="Gobo Silva, Maria Leticia" uniqKey="Gobo Silva M" first="Maria Leticia" last="Gobo Silva">Maria Leticia Gobo Silva</name><affiliation wicri:level="3"><nlm:affiliation>Department of Radiation Therapy, A.C. Camargo Cancer Center, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Department of Radiation Therapy, A.C. Camargo Cancer Center, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Gouin, Francois" sort="Gouin, Francois" uniqKey="Gouin F" first="Francois" last="Gouin">Francois Gouin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Orthopedic Surgery, Centre León Bérard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Orthopedic Surgery, Centre León Bérard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Gronchi, Alessandro" sort="Gronchi, Alessandro" uniqKey="Gronchi A" first="Alessandro" last="Gronchi">Alessandro Gronchi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Haro Varas, Juan Carlos" sort="Haro Varas, Juan Carlos" uniqKey="Haro Varas J" first="Juan Carlos" last="Haro-Varas">Juan Carlos Haro-Varas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.</nlm:affiliation><country xml:lang="fr">Pérou</country><wicri:regionArea>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima</wicri:regionArea><wicri:noRegion>Lima</wicri:noRegion></affiliation></author><author><name sortKey="Jimenez Brenes, Natalia" sort="Jimenez Brenes, Natalia" uniqKey="Jimenez Brenes N" first="Natalia" last="Jiménez-Brenes">Natalia Jiménez-Brenes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, San Vicente de Paúl Hospital, Heredia, Costa Rica.</nlm:affiliation><country xml:lang="fr">Costa Rica</country><wicri:regionArea>Department of Medical Oncology, San Vicente de Paúl Hospital, Heredia</wicri:regionArea><wicri:noRegion>Heredia</wicri:noRegion></affiliation></author><author><name sortKey="Kasper, Bernd" sort="Kasper, Bernd" uniqKey="Kasper B" first="Bernd" last="Kasper">Bernd Kasper</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Mannheim University Medical Center, Mannheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Medical Oncology, Mannheim University Medical Center, Mannheim</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation></author><author><name sortKey="Lopes De Mello, Celso Abdon" sort="Lopes De Mello, Celso Abdon" uniqKey="Lopes De Mello C" first="Celso Abdon" last="Lopes De Mello">Celso Abdon Lopes De Mello</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Maki, Robert" sort="Maki, Robert" uniqKey="Maki R" first="Robert" last="Maki">Robert Maki</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Martinez Delgado, Paula" sort="Martinez Delgado, Paula" uniqKey="Martinez Delgado P" first="Paula" last="Martínez-Delgado">Paula Martínez-Delgado</name><affiliation wicri:level="1"><nlm:affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla</wicri:regionArea><wicri:noRegion>Sevilla</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Said, Hector" sort="Martinez Said, Hector" uniqKey="Martinez Said H" first="Hector" last="Martínez-Said">Hector Martínez-Said</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Martinez Tlahuel, Jorge Luis" sort="Martinez Tlahuel, Jorge Luis" uniqKey="Martinez Tlahuel J" first="Jorge Luis" last="Martinez-Tlahuel">Jorge Luis Martinez-Tlahuel</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, Instituto Nacional de Cancerología, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Surgery, Instituto Nacional de Cancerología, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Morales Perez, Jose Manuel" sort="Morales Perez, Jose Manuel" uniqKey="Morales Perez J" first="Jose Manuel" last="Morales-Pérez">Jose Manuel Morales-Pérez</name><affiliation wicri:level="1"><nlm:affiliation>Radiology Department, University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Radiology Department, University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Mu Oz Casares, Francisco Cristobal" sort="Mu Oz Casares, Francisco Cristobal" uniqKey="Mu Oz Casares F" first="Francisco Cristobal" last="Mu Oz-Casares">Francisco Cristobal Mu Oz-Casares</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Surgery, University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Nakagawa, Suely A" sort="Nakagawa, Suely A" uniqKey="Nakagawa S" first="Suely A" last="Nakagawa">Suely A. Nakagawa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Orthopedics, A.C. Camargo Cancer Center, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Department of Orthopedics, A.C. Camargo Cancer Center, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Ortiz Cruz, Eduardo Jose" sort="Ortiz Cruz, Eduardo Jose" uniqKey="Ortiz Cruz E" first="Eduardo Jose" last="Ortiz-Cruz">Eduardo Jose Ortiz-Cruz</name><affiliation wicri:level="3"><nlm:affiliation>Orthopedic Surgery and Traumatology Department, La Paz University Hospital, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Orthopedic Surgery and Traumatology Department, La Paz University Hospital, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Palmerini, Emanuela" sort="Palmerini, Emanuela" uniqKey="Palmerini E" first="Emanuela" last="Palmerini">Emanuela Palmerini</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Rizzoli Orthopedic Institute, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical Oncology, Rizzoli Orthopedic Institute, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Patel, Shreyaskumar" sort="Patel, Shreyaskumar" uniqKey="Patel S" first="Shreyaskumar" last="Patel">Shreyaskumar Patel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Moura, David S" sort="Moura, David S" uniqKey="Moura D" first="David S" last="Moura">David S. Moura</name><affiliation wicri:level="1"><nlm:affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla</wicri:regionArea><wicri:noRegion>Sevilla</wicri:noRegion></affiliation></author><author><name sortKey="Stacchiotti, Silvia" sort="Stacchiotti, Silvia" uniqKey="Stacchiotti S" first="Silvia" last="Stacchiotti">Silvia Stacchiotti</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Sunyach, Marie Pierre" sort="Sunyach, Marie Pierre" uniqKey="Sunyach M" first="Marie Pierre" last="Sunyach">Marie Pierre Sunyach</name><affiliation wicri:level="3"><nlm:affiliation>Department of Radiation Therapy, Centre León Bérard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Radiation Therapy, Centre León Bérard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Valverde, Claudia M" sort="Valverde, Claudia M" uniqKey="Valverde C" first="Claudia M" last="Valverde">Claudia M. Valverde</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Vall d'Hebron Hospital, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Vall d'Hebron Hospital, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Waisberg, Federico" sort="Waisberg, Federico" uniqKey="Waisberg F" first="Federico" last="Waisberg">Federico Waisberg</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Centre León Bérard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Centre León Bérard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></analytic><series><title level="j">The oncologist</title><idno type="eISSN">1549-490X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID-19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care.</p></div><div type="abstract" xml:lang="en"><p><b>MATERIAL AND METHODS</b></p><p>A total of 125 recommendations were proposed in soft-tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2-3 months, respectively. The consensus level for each recommendation was classified as "strongly recommended" (SR) if more than 90% of experts agreed, "recommended" (R) if 75%-90% of experts agreed and "no consensus" (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European-Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology-Magnitude of clinical benefit scale was applied to systemic-treatment recommendations to support prioritization.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher-priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower-priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>The consensus on 115 of 125 recommendations indicates a high-level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.</p></div><div type="abstract" xml:lang="en"><p><b>IMPLICATIONS FOR PRACTICE</b></p><p>The Sarcoma European-Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID-19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID-19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower-priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology-Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.</p></div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32888360</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-490X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>The oncologist</Title><ISOAbbreviation>Oncologist</ISOAbbreviation></Journal><ArticleTitle>Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2020-0516</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID-19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">A total of 125 recommendations were proposed in soft-tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2-3 months, respectively. The consensus level for each recommendation was classified as "strongly recommended" (SR) if more than 90% of experts agreed, "recommended" (R) if 75%-90% of experts agreed and "no consensus" (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European-Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology-Magnitude of clinical benefit scale was applied to systemic-treatment recommendations to support prioritization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher-priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower-priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The consensus on 115 of 125 recommendations indicates a high-level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.</AbstractText><AbstractText Label="IMPLICATIONS FOR PRACTICE" NlmCategory="CONCLUSIONS">The Sarcoma European-Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID-19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID-19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower-priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology-Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.</AbstractText><CopyrightInformation>© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin-Broto</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7350-6916</Identifier><AffiliationInfo><Affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hindi</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguiar</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Pelvic Surgery, A.C. Camargo Cancer Center, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badilla-González</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of medical oncology, Rafael Ángel Calderón Guardia Hospital, San José, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro-Oliden</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chacón</LastName><ForeName>Matias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Correa-Generoso</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Radiotherapy Department, Virgen de la Victoria University Hospital, Málaga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Álava</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pathology Department, University Hospital Virgen del Rocío, Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERONC, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donati</LastName><ForeName>Davide María</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Unit of Orthopedic Pathology and Osteoarticular Tissue Regeneration, Rizzoli Orthopedic Institute, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Skane University Hospital-Lund, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falla-Jimenez</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Breast and Soft Tissues Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>German</LastName><ForeName>Gisela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Oncológico Provincial, Córdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobo Silva</LastName><ForeName>Maria Leticia</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Radiation Therapy, A.C. Camargo Cancer Center, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouin</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Centre León Bérard, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gronchi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haro-Varas</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiménez-Brenes</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, San Vicente de Paúl Hospital, Heredia, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasper</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Mannheim University Medical Center, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes de Mello</LastName><ForeName>Celso Abdon</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maki</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Delgado</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Said</LastName><ForeName>Hector</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Tlahuel</LastName><ForeName>Jorge Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Surgery, Instituto Nacional de Cancerología, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales-Pérez</LastName><ForeName>Jose Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Radiology Department, University Hospital Virgen del Rocio, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muñoz-Casares</LastName><ForeName>Francisco Cristobal</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Virgen del Rocio, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Suely A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, A.C. Camargo Cancer Center, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz-Cruz</LastName><ForeName>Eduardo Jose</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Orthopedic Surgery and Traumatology Department, La Paz University Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmerini</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Rizzoli Orthopedic Institute, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Shreyaskumar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moura</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stacchiotti</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunyach</LastName><ForeName>Marie Pierre</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Radiation Therapy, Centre León Bérard, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valverde</LastName><ForeName>Claudia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Vall d'Hebron Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waisberg</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blay</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Centre León Bérard, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncologist</MedlineTA><NlmUniqueID>9607837</NlmUniqueID><ISSNLinking>1083-7159</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Guidelines</Keyword><Keyword MajorTopicYN="N">Multidisciplinary</Keyword><Keyword MajorTopicYN="N">Patient care</Keyword><Keyword MajorTopicYN="N">Sarcoma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>5</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32888360</ArticleId><ArticleId IdType="doi">10.1634/theoncologist.2020-0516</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Lazzerini M, Putoto G. COVID-19 in Italy: Momentous decisions and many uncertainties. Lancet Glob Health 2020;8:e641-e642.</Citation></Reference><Reference><Citation>Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol 2020;150:102972.</Citation></Reference><Reference><Citation>Mittal D, Gubin MM, Schreiber RD et al. New insights into cancer immunoediting and its three component phases-Elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25.</Citation></Reference><Reference><Citation>Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009;10:589-597.</Citation></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-1034.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.</Citation></Reference><Reference><Citation>Zheng HY, Zhang M, Yang CX et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol 2020;17:541-543.</Citation></Reference><Reference><Citation>Liang W, Guan W, Chen R et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020;21:335-337.</Citation></Reference><Reference><Citation>Williamson E, Walker AJ, Bhaskaran KJ et al. OpenSAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. Preprint posted online May 7, 2020. doi: https://doi.org/10.1101/2020.05.06.20092999</Citation></Reference><Reference><Citation>Lee LYW, Cazier JB, Angelis V et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet 2020;395:1919-1926.</Citation></Reference><Reference><Citation>Al-Shamsi HO, Alhazzani W, Alhuraiji A et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: An international collaborative group. The Oncologist 2020;25:e936-e945.</Citation></Reference><Reference><Citation>de Joode K, Dumoulin DW, Engelen V et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: The patients' perspective. Eur J Cancer 2020;136:132-139.</Citation></Reference><Reference><Citation>Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: Prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020;17:268-270.</Citation></Reference><Reference><Citation>Selnet. Available at https://selnet-h2020.org/. Accessed May 12, 2020.</Citation></Reference><Reference><Citation>COVID-19 rapid guidline: Delivery of radiotheraphy. National Institute for Health and Care Excellence. Available at https://www.nice.org.uk/guidance/ng162. Accessed May 12, 2020.</Citation></Reference><Reference><Citation>ESMO-EURACAN Management and Treatment Adapted Recommendations in the COVID-19 Era: Sarcomas. Available at https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/sarcomas-in-the-covid-19-era. Accessed May 12, 2020.</Citation></Reference><Reference><Citation>Diamond IR, Grant RC, Feldman BM et al. Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014;67:401-409.</Citation></Reference><Reference><Citation>Cherny NI, Dafni U, Bogaerts J et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 2017;28:2340-2366.</Citation></Reference><Reference><Citation>Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547-1573.</Citation></Reference><Reference><Citation>Bauer HC, Trovik CS, Alvegård TA et al. Monitoring referral and treatment in soft tissue sarcoma: Study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand 2001;72:150-159.</Citation></Reference><Reference><Citation>Mathoulin-Pélissier S, Chevreau C, Bellera C et al. Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: A French prospective population-based study. Ann Oncol 2014;25:225-231.</Citation></Reference><Reference><Citation>Ray-Coquard I, Thiesse P, Ranchère-Vince D et al. Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. Ann Oncol 2004;15:307-315.</Citation></Reference><Reference><Citation>Hoekstra HJ, Haas RLM, Verhoef C et al. Adherence to Guidelines for Adult (Non-GIST) soft tissue sarcoma in The Netherlands: A plea for dedicated sarcoma centers. Ann Surg Oncol 2017;24:3279-3288.</Citation></Reference><Reference><Citation>Martin-Broto J, Hindi N, Cruz J et al. Relevance of reference centers in sarcoma care and quality item evaluation: Results from the prospective registry of the Spanish Group for Research in Sarcoma (GEIS). The Oncologist 2019;24:e338-e346.</Citation></Reference><Reference><Citation>Casali PG, Bielack S, Abecassis N et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv79-iv95.</Citation></Reference><Reference><Citation>Casali PG, Abecassis N, Aro HT et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv268-iv269.</Citation></Reference><Reference><Citation>Casali PG, Abecassis N, Aro HT et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv68-iv78.</Citation></Reference><Reference><Citation>Burki TK. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol 2020;21:629-630.</Citation></Reference><Reference><Citation>van de Haar J, Hoes LR, Coles CE et al. Caring for patients with cancer in the COVID-19 era. Nat Med 2020;26:665-671.</Citation></Reference><Reference><Citation>COVID-19 rapid guideline: Delivery of systemic anticancer treatments. National Institute for Health and Care Excellence. Available at https://www.nice.org.uk/guidance/ng161. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>Resource for Management Options of Sarcoma During COVID-19. Society of Surgical Oncology. Available at https://www.surgonc.org/wp-content/uploads/2020/03/Sarcoma-Resource-during-COVID-19-3.30.20.pdf. Accessed May 14, 2020.</Citation></Reference><Reference><Citation>Dinmohamed AG, Visser O, Verhoeven RHA et al. Fewer cancer diagnoses during the COVID-19 epidemic in The Netherlands. Lancet Oncol 2020;21:750-751.</Citation></Reference><Reference><Citation>Waggoner J, Carline JD, Durning SJ. Is there a consensus on consensus methodology? Descriptions and recommendations for future consensus research. Acad Med 2016;91:663-668.</Citation></Reference><Reference><Citation>Casali PG, Abecassis N, Bauer S et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(suppl 4):iv51-iv67.</Citation></Reference><Reference><Citation>Rothermundt C, Whelan JS, Dileo P et al. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer 2014;110:2420-2426.</Citation></Reference><Reference><Citation>Lindner LH, Litière S, Sleijfer S et al. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Int J Cancer 2018;142:2610-2620.</Citation></Reference><Reference><Citation>Hompland I, Bruland ØS, Holmebakk T et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: Analysis of a large, single-institution cohort. Acta Oncol 2017;56:1317-1323.</Citation></Reference><Reference><Citation>Rutkowski P, Andrzejuk J, Bylina E et al. What are the current outcomes of advanced gastrointestinal stromal tumors: Who are the long-term survivors treated initially with imatinib? Med Oncol 2013;30:765.</Citation></Reference><Reference><Citation>Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.</Citation></Reference><Reference><Citation>Wheatley K, Moroz V, Marec-Berard P et al. First results of the EURO EWING 2012 (EE2012) trial comparing two chemotherapy regimens in newly diagnosed Ewing Sarcoma (ES). Poster presented at CTOS Annual meeting, Tokyo, Japan: November 13-16, 2019;48.</Citation></Reference><Reference><Citation>Oberlin O, Rey A, Sanchez de Toledo J et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: Long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 2012;30:2457-2465.</Citation></Reference><Reference><Citation>Bisogno G, Jenney M, Bergeron C et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): A multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 2018;19:1061-1071.</Citation></Reference><Reference><Citation>Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-1247.</Citation></Reference><Reference><Citation>Gronchi A, Ferrari S, Quagliuolo V et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 2017;18:812-822.</Citation></Reference><Reference><Citation>Gronchi A, Palmerini E, Quagliuolo V et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol 2020;38:2178-2186.</Citation></Reference><Reference><Citation>Schöffski P, Chawla S, Maki RG et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387:1629-1637.</Citation></Reference><Reference><Citation>Demetri GD, von Mehren M, Jones RL et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016;34:786-793.</Citation></Reference><Reference><Citation>Kawai A, Araki N, Sugiura H et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: A randomised, open-label, phase 2 study. Lancet Oncol 2015;16:406-416.</Citation></Reference><Reference><Citation>van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-1886.</Citation></Reference><Reference><Citation>García-Del-Muro X, López-Pousa A, Maurel J et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: A Spanish Group for Research on Sarcomas study. J Clin Oncol 2011;29:2528-2533.</Citation></Reference><Reference><Citation>Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007;25:2755-2763.</Citation></Reference><Reference><Citation>Pautier P, Floquet A, Penel N et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). The Oncologist 2012;17:1213-1220.</Citation></Reference><Reference><Citation>Buesa JM, López-Pousa A, Martín J et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998;9:871-876.</Citation></Reference><Reference><Citation>Benjamin RS, Wiernik PH, Bachur NR. Adriamycin: A new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol 1975;1:63-76.</Citation></Reference><Reference><Citation>Eilber F, Giuliano A, Eckardt J et al. Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J Clin Oncol 1987;5:21-26.</Citation></Reference><Reference><Citation>Bernthal NM, Federman N, Eilber FR et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer 2012;118:5888-5893.</Citation></Reference><Reference><Citation>Meyers PA, Schwartz CL, Krailo MD et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the Children's Oncology Group. J Clin Oncol 2008;26:633-638.</Citation></Reference><Reference><Citation>Ochs JJ, Freeman AI, Douglass HO, Jr. et al. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 1978;62:239-245.</Citation></Reference><Reference><Citation>Voute PA, Souhami RL, Nooij M et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol 1999;10:1211-1218.</Citation></Reference><Reference><Citation>Gentet JC, Brunat-Mentigny M, Demaille MC et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 1997;33:232-237.</Citation></Reference><Reference><Citation>Berrak SG, Pearson M, Berberoglu S et al. High-dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity. Pediatr Blood Cancer 2005;44:215-219.</Citation></Reference><Reference><Citation>Grignani G, Palmerini E, Ferraresi V et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol 2015;16:98-107.</Citation></Reference><Reference><Citation>Duffaud F, Mir O, Boudou-Rouquette P et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: A non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 2019;20:120-133.</Citation></Reference><Reference><Citation>McCabe MG, Moroz V, Khan M et al. Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. J Clin Oncol 2019;37:11007a.</Citation></Reference><Reference><Citation>Mora J, Castañeda A, Perez-Jaume S et al. GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS). Br J Cancer 2017;117:767-774.</Citation></Reference><Reference><Citation>Meazza C, Casanova M, Luksch R et al. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma. Pediatr Blood Cancer 2010;55:617-620.</Citation></Reference><Reference><Citation>Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 2012;307:1265-1272.</Citation></Reference><Reference><Citation>van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001;358:1421-1423.</Citation></Reference><Reference><Citation>Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-1338.</Citation></Reference><Reference><Citation>Demetri GD, Garrett CR, Schöffski P et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012;18:3170-3179.</Citation></Reference><Reference><Citation>Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302.</Citation></Reference><Reference><Citation>von Mehren M, Serrano C, Bauer S et al. INVICTUS: A phase 3, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (nct03353753). Ann Oncol 2019;30(suppl 5):v851-v934.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Argentine</li><li>Brésil</li><li>Costa Rica</li><li>Espagne</li><li>France</li><li>Italie</li><li>Mexique</li><li>Pérou</li><li>Suède</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Bade-Wurtemberg</li><li>Catalogne</li><li>Communauté de Madrid</li><li>District de Karlsruhe</li><li>Lombardie</li><li>Pennsylvanie</li><li>Rhône-Alpes</li><li>Texas</li><li>État de São Paulo</li></region><settlement><li>Barcelone</li><li>Lyon</li><li>Madrid</li><li>Mannheim</li><li>Milan</li><li>São Paulo</li></settlement></list><tree><country name="Espagne"><noRegion><name sortKey="Martin Broto, Javier" sort="Martin Broto, Javier" uniqKey="Martin Broto J" first="Javier" last="Martin-Broto">Javier Martin-Broto</name></noRegion><name sortKey="Correa Generoso, Raquel" sort="Correa Generoso, Raquel" uniqKey="Correa Generoso R" first="Raquel" last="Correa-Generoso">Raquel Correa-Generoso</name><name sortKey="De Lava, Enrique" sort="De Lava, Enrique" uniqKey="De Lava E" first="Enrique" last="De Lava">Enrique De Lava</name><name sortKey="De Lava, Enrique" sort="De Lava, Enrique" uniqKey="De Lava E" first="Enrique" last="De Lava">Enrique De Lava</name><name sortKey="De Lava, Enrique" sort="De Lava, Enrique" uniqKey="De Lava E" first="Enrique" last="De Lava">Enrique De Lava</name><name sortKey="Hindi, Nadia" sort="Hindi, Nadia" uniqKey="Hindi N" first="Nadia" last="Hindi">Nadia Hindi</name><name sortKey="Hindi, Nadia" sort="Hindi, Nadia" uniqKey="Hindi N" first="Nadia" last="Hindi">Nadia Hindi</name><name sortKey="Martin Broto, Javier" sort="Martin Broto, Javier" uniqKey="Martin Broto J" first="Javier" last="Martin-Broto">Javier Martin-Broto</name><name sortKey="Martinez Delgado, Paula" sort="Martinez Delgado, Paula" uniqKey="Martinez Delgado P" first="Paula" last="Martínez-Delgado">Paula Martínez-Delgado</name><name sortKey="Morales Perez, Jose Manuel" sort="Morales Perez, Jose Manuel" uniqKey="Morales Perez J" first="Jose Manuel" last="Morales-Pérez">Jose Manuel Morales-Pérez</name><name sortKey="Moura, David S" sort="Moura, David S" uniqKey="Moura D" first="David S" last="Moura">David S. Moura</name><name sortKey="Mu Oz Casares, Francisco Cristobal" sort="Mu Oz Casares, Francisco Cristobal" uniqKey="Mu Oz Casares F" first="Francisco Cristobal" last="Mu Oz-Casares">Francisco Cristobal Mu Oz-Casares</name><name sortKey="Ortiz Cruz, Eduardo Jose" sort="Ortiz Cruz, Eduardo Jose" uniqKey="Ortiz Cruz E" first="Eduardo Jose" last="Ortiz-Cruz">Eduardo Jose Ortiz-Cruz</name><name sortKey="Valverde, Claudia M" sort="Valverde, Claudia M" uniqKey="Valverde C" first="Claudia M" last="Valverde">Claudia M. Valverde</name></country><country name="Brésil"><region name="État de São Paulo"><name sortKey="Aguiar, Samuel" sort="Aguiar, Samuel" uniqKey="Aguiar S" first="Samuel" last="Aguiar">Samuel Aguiar</name></region><name sortKey="Gobo Silva, Maria Leticia" sort="Gobo Silva, Maria Leticia" uniqKey="Gobo Silva M" first="Maria Leticia" last="Gobo Silva">Maria Leticia Gobo Silva</name><name sortKey="Lopes De Mello, Celso Abdon" sort="Lopes De Mello, Celso Abdon" uniqKey="Lopes De Mello C" first="Celso Abdon" last="Lopes De Mello">Celso Abdon Lopes De Mello</name><name sortKey="Nakagawa, Suely A" sort="Nakagawa, Suely A" uniqKey="Nakagawa S" first="Suely A" last="Nakagawa">Suely A. Nakagawa</name></country><country name="Costa Rica"><noRegion><name sortKey="Badilla Gonzalez, Ronald" sort="Badilla Gonzalez, Ronald" uniqKey="Badilla Gonzalez R" first="Ronald" last="Badilla-González">Ronald Badilla-González</name></noRegion><name sortKey="Jimenez Brenes, Natalia" sort="Jimenez Brenes, Natalia" uniqKey="Jimenez Brenes N" first="Natalia" last="Jiménez-Brenes">Natalia Jiménez-Brenes</name></country><country name="Pérou"><noRegion><name sortKey="Castro Oliden, Victor" sort="Castro Oliden, Victor" uniqKey="Castro Oliden V" first="Victor" last="Castro-Oliden">Victor Castro-Oliden</name></noRegion><name sortKey="Falla Jimenez, Martin" sort="Falla Jimenez, Martin" uniqKey="Falla Jimenez M" first="Martin" last="Falla-Jimenez">Martin Falla-Jimenez</name><name sortKey="Haro Varas, Juan Carlos" sort="Haro Varas, Juan Carlos" uniqKey="Haro Varas J" first="Juan Carlos" last="Haro-Varas">Juan Carlos Haro-Varas</name></country><country name="Argentine"><noRegion><name sortKey="Chac N, Matias" sort="Chac N, Matias" uniqKey="Chac N M" first="Matias" last="Chac N">Matias Chac N</name></noRegion><name sortKey="German, Gisela" sort="German, Gisela" uniqKey="German G" first="Gisela" last="German">Gisela German</name><name sortKey="Waisberg, Federico" sort="Waisberg, Federico" uniqKey="Waisberg F" first="Federico" last="Waisberg">Federico Waisberg</name></country><country name="Italie"><noRegion><name sortKey="Donati, Davide Maria" sort="Donati, Davide Maria" uniqKey="Donati D" first="Davide María" last="Donati">Davide María Donati</name></noRegion><name sortKey="Gronchi, Alessandro" sort="Gronchi, Alessandro" uniqKey="Gronchi A" first="Alessandro" last="Gronchi">Alessandro Gronchi</name><name sortKey="Palmerini, Emanuela" sort="Palmerini, Emanuela" uniqKey="Palmerini E" first="Emanuela" last="Palmerini">Emanuela Palmerini</name><name sortKey="Stacchiotti, Silvia" sort="Stacchiotti, Silvia" uniqKey="Stacchiotti S" first="Silvia" last="Stacchiotti">Silvia Stacchiotti</name></country><country name="Suède"><noRegion><name sortKey="Eriksson, Mikael" sort="Eriksson, Mikael" uniqKey="Eriksson M" first="Mikael" last="Eriksson">Mikael Eriksson</name></noRegion></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Gouin, Francois" sort="Gouin, Francois" uniqKey="Gouin F" first="Francois" last="Gouin">Francois Gouin</name></region><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><name sortKey="Sunyach, Marie Pierre" sort="Sunyach, Marie Pierre" uniqKey="Sunyach M" first="Marie Pierre" last="Sunyach">Marie Pierre Sunyach</name></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Kasper, Bernd" sort="Kasper, Bernd" uniqKey="Kasper B" first="Bernd" last="Kasper">Bernd Kasper</name></region></country><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Maki, Robert" sort="Maki, Robert" uniqKey="Maki R" first="Robert" last="Maki">Robert Maki</name></region><name sortKey="Patel, Shreyaskumar" sort="Patel, Shreyaskumar" uniqKey="Patel S" first="Shreyaskumar" last="Patel">Shreyaskumar Patel</name></country><country name="Mexique"><noRegion><name sortKey="Martinez Said, Hector" sort="Martinez Said, Hector" uniqKey="Martinez Said H" first="Hector" last="Martínez-Said">Hector Martínez-Said</name></noRegion><name sortKey="Martinez Tlahuel, Jorge Luis" sort="Martinez Tlahuel, Jorge Luis" uniqKey="Martinez Tlahuel J" first="Jorge Luis" last="Martinez-Tlahuel">Jorge Luis Martinez-Tlahuel</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000650 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000650 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32888360
|texte= Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32888360" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |